Overview
Herpetic gingivostomatitis (HGS), primarily caused by the herpes simplex virus type 1 (HSV-1), is a common viral infection characterized by significant oral and extra-oral manifestations. This condition predominantly affects children and young adults, with notable peaks in incidence observed in early childhood (6 months to 5 years) and early adulthood (around 20 years). The clinical presentation often includes systemic symptoms followed by painful oral ulcers and inflamed gingiva, leading to significant morbidity. Early recognition and appropriate management are crucial to mitigate symptoms and prevent complications. Understanding the epidemiology, clinical features, diagnostic criteria, and effective management strategies is essential for healthcare providers to optimize patient care.
Epidemiology
Primary herpetic gingivostomatitis (PHGS) is notably prevalent, affecting approximately 25–30% of children and adolescents. The disease exhibits two distinct peaks in incidence: the first in infants and young children aged 6 months to 5 years, likely due to their initial exposure to HSV-1, and the second in young adults around 20 years old, possibly reflecting reactivation of latent virus or new infections in a more socially active population [PMID:33993407]. These age-specific patterns highlight the importance of targeted preventive measures and awareness campaigns in these demographic groups. The high incidence underscores the need for clinicians to maintain a high index of suspicion for HSV-1 infection in patients presenting with characteristic symptoms, particularly during these peak periods.
Clinical Presentation
The clinical presentation of PHGS is multifaceted, beginning with systemic symptoms that often precede the characteristic oral lesions. Patients typically experience a prodrome phase characterized by fever, chills, nausea, loss of appetite, lethargy, irritability, malaise, and headache [PMID:33993407]. These systemic manifestations can mimic other viral illnesses, necessitating a thorough clinical evaluation to identify specific oral and extra-oral signs. Following the prodromal phase, the hallmark features emerge, including painful vesicles that coalesce into ulcers, particularly affecting the lips, tongue, buccal mucosa, and gingiva, which often become edematous and prone to bleeding [PMID:33993407]. The severity of pain can be profound, significantly impacting a patient's quality of life. Studies utilizing tools such as the Visual Analogue Scale (VAS) and the McGill Pain Questionnaire (MPQ) have quantified this pain, demonstrating its substantial impact on daily activities and necessitating effective pain management strategies [PMID:35504550]. Additionally, elevated levels of inflammatory markers, such as C-reactive protein (CRP), averaging around 7.4 mg/dl in affected children, indicate a robust inflammatory response, further complicating clinical management [PMID:25558699].
Diagnosis
Diagnosing PHGS involves a combination of clinical presentation and laboratory support. In a study of 66 children diagnosed with PHGS, elevated CRP levels (average 7.4 mg/dl) were observed, with over a third of patients showing CRP levels above 7 mg/dl, highlighting the significant inflammatory component of the disease [PMID:25558699]. Laboratory tests, including PCR for HSV-1 DNA and serological assays, can confirm the diagnosis when clinical suspicion is high. However, in practice, the characteristic clinical features often guide initial management decisions. Viral culture and direct fluorescent antibody testing of vesicular fluid or ulcer scrapings can also provide definitive evidence of HSV-1 infection, though these methods may not always be readily available or timely. The integration of clinical judgment with laboratory findings ensures accurate diagnosis and timely intervention.
Management
The management of PHGS aims to alleviate symptoms, reduce viral replication, and prevent complications. Early initiation of antiviral therapy within the first 72 hours of symptom onset is recommended for adolescents with clear signs of gingivostomatitis, significant pain, or dehydration [PMID:33993407]. Commonly prescribed antivirals include acyclovir, valacyclovir, and famciclovir, which effectively shorten the duration of symptoms and reduce viral shedding. Beyond antiviral therapy, supportive care is crucial. Nutritional support through pureed diets or supplements is advised to ensure adequate nutrition despite oral discomfort. Systemic analgesics, such as paracetamol, are essential for managing pain and associated malaise, improving patient comfort and compliance with treatment [PMID:33993407].
Emerging evidence supports the adjunctive use of topical therapies and innovative treatments. A randomized controlled trial demonstrated that combining topical antiviral therapy with photodynamic therapy (aPDT) significantly improved pain scores and reduced HSV-1 levels and pro-inflammatory cytokines (IL-6 and TNF-α) compared to monotherapy approaches [PMID:35504550]. This suggests that multimodal therapy could offer enhanced therapeutic benefits. Additionally, natural compounds like those found in an ointment containing 5% crude phenolic compounds from Rhododendron ungernii leaves (Rodopes) have shown promise in animal models, accelerating wound healing and tissue regeneration without signs of bacterial contamination, potentially mitigating complications related to prolonged healing [PMID:22573755]. These findings highlight the potential for complementary therapies in enhancing recovery and reducing the duration of symptoms.
Complications
Complications of PHGS can arise from both the severity of the primary infection and delayed or inadequate treatment. Prolonged healing periods can lead to secondary bacterial infections, particularly in the context of compromised oral mucosa. However, studies indicate that interventions like the use of Rodopes ointment can accelerate scab rejection and promote faster re-epithelialization, thereby reducing the risk of secondary infections and associated complications [PMID:22573755]. Other potential complications include dehydration due to poor oral intake and, in rare cases, more severe systemic involvement such as encephalitis, though these are less common. Early and effective management can significantly mitigate these risks, emphasizing the importance of prompt diagnosis and intervention.
Prognosis & Follow-up
The prognosis for PHGS is generally favorable with appropriate management, though the recovery timeline can vary. Follow-up assessments conducted at multiple intervals—baseline, immediate post-treatment, and at two weeks, four weeks, three months, and six months—have shown sustained improvements in pain reduction and decreased viral loads in patients treated with combined therapies, including topical antivirals and aPDT [PMID:35504550]. These outcomes underscore the importance of continued monitoring to ensure sustained recovery and to address any lingering symptoms or complications promptly. Regular follow-ups also allow healthcare providers to reassess the need for ongoing supportive care and to provide psychological support, given the significant impact of the illness on daily functioning.
Special Populations
Young patients, particularly those under five years old, frequently present to dental clinics due to the prominent oral lesions characteristic of PHGS, highlighting the critical role of dental professionals in early recognition and initial management [PMID:33993407]. Adolescents, especially those in their early twenties, also constitute a significant group affected by PHGS, often due to reactivation of latent HSV-1 or new infections. In these populations, collaboration between pediatricians, dentists, and primary care providers is essential for comprehensive care. Special attention should be paid to ensuring adequate pain management and nutritional support, as these factors significantly influence recovery and overall well-being in these vulnerable groups. Additionally, educating parents and caregivers about the importance of hygiene practices and the potential for viral transmission can help prevent outbreaks within households and communities.
References
1 Bardellini E, Amadori F, Veneri F, Conti G, Paderno A, Majorana A. Adolescents and primary herpetic gingivostomatitis: an Italian overview. Irish journal of medical science 2022. link 2 Vellappally S, Mahmoud MH, Alaqeel SM, Alotaibi RN, Almansour H, Alageel O et al.. Efficacy of antimicrobial photodynamic therapy versus antiviral therapy in the treatment of herpetic gingivostomatitis among children: Aa randomized controlled clinical trial. Photodiagnosis and photodynamic therapy 2022. link 3 Nevet A, Yarden-Bilavsky H, Ashkenazi S, Livni G. C-Reactive protein levels in children with primary herpetic gingivostomatitis. The Israel Medical Association journal : IMAJ 2014. link 4 Mulkidzhanian KG, Novikova ZhN, Sulakvelidze MT, Shalashvili KG, Kemertelidze EP. Antiviral drug rodopes: evaluation of wound healing activity. Georgian medical news 2012. link
4 papers cited of 5 indexed.